Skip to main content
SpringerLink
Log in

Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

The effects of pituitary suppression with one-third depot of long-acting gonadotropin-releasing hormone (GnRH) agonist in GnRH agonist long protocol for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) were investigated. A retrospective cohort study was performed on 3186 cycles undergoing IVF/ICSI with GnRH agonist long protocol in a university-affiliated infertility center. The pituitary was suppressed with depot triptorelin of 1.25 mg or 1.875 mg. There was no significant difference in live birth rate between 1.25 mg triptorelin group and 1.875 mg triptorelin group (41.2% vs. 43.7%). The mean luteinizing hormone (LH) level on follicle-stimulating hormone (FSH) starting day was significantly higher in 1.25 mg triptorelin group. The mean LH level on the day of human chorionic gonadotrophin (hCG) administration was slightly but statistically higher in 1.25 mg triptorelin group. There was no significant difference in the total FSH dose between the two groups. The number of retrieved oocytes was slightly but statistically less in 1.25 mg triptorelin group than in 1.875 mg triptorelin group (12.90±5.82 vs. 13.52±6.97). There was no significant difference in clinical pregnancy rate between the two groups (50.5% vs. 54.5%). It was suggested that one-third depot triptorelin can achieve satisfactory pituitary suppression and produce good live birth rates in a long protocol for IVF/ICSI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tan SL. Luteinizing hormone-releasing hormone agonist for ovarian stimulation in assisted reproduction. Curr Opin Obstet Gynecol, 1994,6(2):166–172

    CAS  PubMed  Google Scholar 

  2. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev, 2000,2:CD001299

    PubMed  Google Scholar 

  3. Geber S, Sales L, Sampaio MA. Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. J Assist Reprod Genet, 2002,19(7):313–318

    Article  PubMed  PubMed Central  Google Scholar 

  4. Orvieto R, Kerner R, Krissi H, et al. Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. Fertil Steril, 2002,78(6):1268–1271

    Article  PubMed  Google Scholar 

  5. Ben-Rafael Z, Lipitz S, Bider D, et al. Ovarian hyporesponsiveness in combined gonadotrophin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril, 1991,55(2):272–275

    CAS  PubMed  Google Scholar 

  6. Balasch J, Gomez F, Casamitjana R, et al. Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot. Hum Reprod, 1992,7(9):1230–1234

    CAS  PubMed  Google Scholar 

  7. Yim SF, Lok IH, Cheung LP, et al. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF. Hum Reprod, 2001,16(3):492–494

    Article  CAS  PubMed  Google Scholar 

  8. Dal Prato L, Borini A, Coticchio G, et al. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study. Hum Reprod, 2004,19(10):2200–2205

    Article  CAS  PubMed  Google Scholar 

  9. Griesinger G, Schultze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod, 2005,20(5):1200–1206

    Article  CAS  PubMed  Google Scholar 

  10. Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod, 1998,13(7):1788–1792

    Article  CAS  PubMed  Google Scholar 

  11. Tsai HD, Chen CM, Lo HY, et al. Subcutaneous low dose leuprolide acetate depot versus leuprolide acetate for women undergoing ovarian stimulation for in-vitro fertilization. Hum Reprod, 1995,10(11):2909–2912

    CAS  PubMed  Google Scholar 

  12. Hsieh Y, Tsai H, Chang C, et al. Comparison of a single half-dose, long acting form of gonadotrophin-releasing hormone analog (GnRH-a) and a short acting form of GnRH-a for pituitary suppression in a controlled ovarian hyperstimulation program. Fertil Steril, 2000,73(4):817–820

    Article  CAS  PubMed  Google Scholar 

  13. El-Nemr A, Bhide M, Khalifa Y, et al. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur J Obstet Gynecol Reprod Biol, 2002,103(2):140–145

    Article  CAS  PubMed  Google Scholar 

  14. Isikoglu M, Ozdem S, Berkkanoglu M, et al. Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Hum Reprod, 2007,22(6):1657–1661

    Article  CAS  PubMed  Google Scholar 

  15. Kaur K, Allahbadia GN, Kadam K, et al. The impact of low dose depot Leuprolide Acetate administration in ART patients—A multicentric study (abstract). Fertil Steril, 2004,82(Suppl 2):S119–S120

    Article  Google Scholar 

  16. Li Y, Yang D, Zhang Q. Clinical outcome of one third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation. Fertil Steril, 2008,90(Suppl):S235

    Article  Google Scholar 

  17. Chen S, Chen X, Luo C, et al. Half-dose and one third-dose depot triptorelin in pituitary suppression for controlled ovarian stimulation in IVF/ICSI-ET: a retrospective study. Hum Reprod, 2010, 25(Suppl):i316

    Google Scholar 

  18. Li Y, Yang D, Zhang Q. Clinical outcome of one-third-dose depot triptorelin is the same as half-dose depot triptorelin in the long protocol of controlled ovarian stimulation. J Hum Reprod Sci, 2012,5(1):14–19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Westergaard JG, Erb K, Laursen SB, et al. Human menopausal gonadotrophin versus recombinant follicle stimulating hormone in normogonadotropic women down-regulated with a gonadotrophinreleasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmatic sperm injection: a prospective randomised study. Fertil Steril, 2001,76(3):543–549

    Article  CAS  PubMed  Google Scholar 

  20. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod, 2000,15(5):1003–1008

    Article  CAS  PubMed  Google Scholar 

  21. Casan EM, Raga F, Polan ML. GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod, 1999,5(3):234–239

    Article  CAS  PubMed  Google Scholar 

  22. Raga F, Casan EM, Kruessel J, et al. The role of gonadotrophin-releasing hormone in murine preimplantation embryonic development. Endocrinology, 1999,140(8):3705–3712

    CAS  PubMed  Google Scholar 

  23. Grundker C, Gunthert AR, Westphalen S, et al. Biology of the gonadotrophin-releasing hormone system in gynecological cancers. Eur J Endocrinol, 2002,146(1):1–14

    Article  CAS  PubMed  Google Scholar 

  24. Ramakrishnappa N, Rajamahendran R, Lin YM, et al. GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci, 2005,88(1-2):95–113

    Article  CAS  PubMed  Google Scholar 

  25. Dor J, Bider D, Shulman A, et al. Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro—results of a prospective, randomized in-vitro fertilization study, Hum Reprod, 2000,15(6):1225–1230

    Article  CAS  PubMed  Google Scholar 

  26. Monroe SE, Blumenfeld Z, Andreyko JL, et al. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab, 1986,63(6):1334–1341

    Article  CAS  PubMed  Google Scholar 

  27. Broekmans FJ, Hompes PGA, Lambalk CB, et al. Short term pituitary desensitization: effect of different does of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod, 1996,11(1):55–60

    Article  CAS  PubMed  Google Scholar 

  28. Cui W, Zhen X, Yang B, et al. The clinical study of optimal dose of Decapeptyle for poor ovarian response patients in IVF-ET cycles. Prog Obstet Gynecol, 2006,15(3):203–205

    Google Scholar 

  29. Janssens RM, Lambalk CB, Vermeiden JP, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod, 2000,15(11):2333–2340

    Article  CAS  PubMed  Google Scholar 

  30. Gelety TJ, Pearlstone AC, Surrey ES. Short-term endocrine response to gonadotrophin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril, 1995,64(6):1074–1080

    CAS  PubMed  Google Scholar 

  31. Mayer A, Lunenfeld E, Wiznitzer A, et al. Increased prevalence of gestational diabetes mellitus in in vitro fertilization pregnancies inadvertently conceived during treatment with long-acting triptorelin acetate. Fertil Steril, 2005,84(3): 789–792

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

    Xin Chen  (陈 薪), Shu-xian Feng  (冯淑娴), Ping-ping Guo  (郭萍萍), Yu-xia He  (何于夏), Yu-dong Liu  (刘玉东), De-sheng Ye  (叶德盛) & Shi-ling Chen  (陈士岭)

Authors
  1. Xin Chen  (陈 薪)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-xian Feng  (冯淑娴)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping-ping Guo  (郭萍萍)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-xia He  (何于夏)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-dong Liu  (刘玉东)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. De-sheng Ye  (叶德盛)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shi-ling Chen  (陈士岭)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shi-ling Chen  (陈士岭).

Additional information

This project was supported by grants from Milstein Medical Asian American Partnership Foundation Fellowship Award in Reproductive Medicine, National Natural Science Foundation of China (No. 81170574 and No. 81401177), Guangdong Province Natural Science Foundation of China (No. 2015A030313286), and Nanfang Hospital High-level Project Matching Funds in 2012 (No. G201206) and 2014 (No. G2014005).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, X., Feng, Sx., Guo, Pp. et al. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 36, 215–220 (2016). https://doi.org/10.1007/s11596-016-1569-8

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-016-1569-8

Key words

Search

Navigation